Results 81 to 90 of about 1,997 (174)

Intensive Combination LDL-Lowering Therapy in a Patient With Homozygous Familial Hypercholesterolemia

JACC: Case Reports
We present a young boy with a diagnosis of homozygous familial hypercholesterolemia who presented with statin and ezetimibe resistance. The patient received lipoprotein apheresis at 6 years of age.
Hayato Tada, MD, Hirofumi Okada, MD, Masa-aki Kawashiri, MD, Masayuki Takamura, MD   +3 more
doaj   +1 more source

Real-world safety and efficacy of lomitapide in homozygous familial hypercholesterolemia: interim report of special-use survey in Japan.

Future Cardiology
Aim: To evaluate the safety and efficacy of lomitapide in real-world clinical practice in Japan. Patients & methods: Interim analysis of 39 patients with homozygous familial hypercholesterolemia from an all-case surveillance study.
M. Harada-Shiba, S. Haruna, Noriaki Kogawa   +2 more
semanticscholar   +1 more source

Lomitapide in homozygous familial hypercholesterolemia: cardiology perspective from a single-center experience

, 2018
AIMS: Homozygous familial hypercholesterolemia (HoFH) is a genetic dyslipidemia characterized by elevated levels of low-density lipoprotein cholesterol (LDL-C) and accelerated atherosclerosis.
Gragnano F, Sperlongano, Rossella, Russo, Maria giovanna, Marcello Arca, Arca M, D'Erasmo L, D'Erasmo, Laura, Calabrò P, Gragnano, Felice, Golia E, Giuseppe Limongelli, Russo M, Mario Crisci, Laura D’Erasmo, Natale F, Enrica Golia, Natale, Francesco, Concilio C, Simona Sperlongano, Rossella Sperlongano, Fabio Fimiani, Calabrò, Paolo, Limongelli G, Arca, Marcello, Cesaro A, Fimiani, Fabio, Cesaro, Arturo, Crisci M, Crisci, Mario, Golia, Enrica, Paolo Calabrò, Sperlongano R, Mariagiovanna Russo, Sperlongano S, Arturo Cesaro, Fimiani F, Claudia Concilio, Francesco Natale, Limongelli, Giuseppe, Concilio, Claudia, Sperlongano, Simona, Felice Gragnano   +41 more
core   +1 more source

Additional file 2 of Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retrospective survey

, 2021
Additional file 2: Figure 1. LDL-C burden according to lomitapide or LA treatment. A Box plot graphs represent the median values of cumulative LDL-C burden in the Lomitapide cohort (dark grey) and in the LA cohort (light grey). For the total LDL-C burden
Antonina Giammanco (5330255), Eric Bruckert (157136), Francesco Sbrana (2963376), Patrizia Suppressa (5330261), Arturo Puja (11410728), Giuliana Fortunato (11410725), Fabio Fimiani (11410734), Laura Calabresi (545881), Maurizio Averna (564584), Katia Bonomo (5330237), Tiziana Sampietro (5330240), Alessia Di Costanzo (11410716), Fabio Nota (11410731), Arturo Cesaro (11410737), Marco Bucci (808435), Randa Bittar (421268), Angelo Baldassare Cefalù (5330264), Antonio Gallo (340926), Olga Kalmykova (11410746), Giovanni Battista Vigna (5330252), Sergio D’Addato (1634032), Laura D’Erasmo (11410713), Alessio Buonaiuto (11410719), Silvia Palmisano (11410740), Livia Pisciotta (10159490), Stefano Bertolini (11410743), Paolo Calabrò (4529500), Tiziana Montalcini (4068379), Samir Saheb (249824), Sophie Béliard (11410749), Marcello Arca (727949), Alain Carrié (10053156), Chiara Pavanello (4846771), Gabriella Iannuzzo (11410722), Carlo Sabbà (427739)   +34 more
core   +1 more source

Modeling hypercholesterolemia and vascular lipid accumulation in LDL receptor mutant zebrafish

Journal of Lipid Research, 2018
Elevated plasma LDL cholesterol is the dominant risk factor for the development of atherosclerosis and cardiovascular disease. Deficiency in the LDL receptor (LDLR) is a major cause of familial hypercholesterolemia in humans, and the LDLR knockout mouse ...
Chao Liu, Young Sook Kim, Jungsu Kim, Jennifer Pattison, Andrés Kamaid, Yury I. Miller   +5 more
doaj   +1 more source

Inhibition of hepatic microsomal triglyceride transfer protein – a novel therapeutic option for treatment of homozygous familial hypercholesterolemia

Vascular Health and Risk Management, 2014
Alpo Vuorio,1,2 Matti J Tikkanen,3 Petri T Kovanen4 1Health Center Mehiläinen, Vantaa, Finland; 2Finnish Institute of Occupational Health, Lappeenranta, Finland; 3Heart and Lung Center, Helsinki University Central Hospital, Folkhälsan Research ...
Vuorio A, Tikkanen MJ, Kovanen PT
doaj  

Comparison of γ-Oryzanol Content Using HPLC Profiling and Bioactivity in Three Indonesian Brown Rice (Oryza sativa L.) Varieties

Indonesian Journal of Chemistry
Brown rice (BrR) is a nutrient-rich staple food and a potential source of γ-oryzanol, which has the potential to promote health effects in hypercholesterolemia.
Ja’far Umar, Christine Natalia Palis, Eko Suyanto, Turhadi Turhadi, Titin Andri Wihastuti, Fatchiyah Fatchiyah   +5 more
doaj   +1 more source

Apheresis Treatment does not Affect the Lipid-Lowering Efficacy of Lomitapide, a Microsomal Triglyceride Transfer Protein Inhibitor, in Patients with Homozygous Familial Hypercholesterolemia

, 2012
BACKGROUND: Patients with Homozygous Familial Hypercholesterolemia (HoFH) are at very high risk for premature cardiovascular disease and are refractory to existing lipid lowering drug therapy.
Leanne T. Bloedon, Dirk Blom, Marina Cuchel, Daniel Gaudet, Maurizio Averna, D. U. Plessis Ame, Daniel J. Rader, Cesare Sirtori, H. Du Toit Theron, A. D. Marais, Giovanni B. Vigna, Robert A. Hegele, Emma A. Meagher, STEFANUTTI, Claudia, 3. Hofh Lomitapide Study Investigators Phase, Prediman K. Shah   +15 more
core  

The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: A modelling analysis

, 2017
Background Patients with homozygous familial hypercholesterolemia are at high risk of cardiovascular disease due to high low-density lipoprotein (LDL)-cholesterol levels. Cardiovascular disease outcome studies are impossible to conduct, due to the rarity
Leipold, Robert, Ishak, Jack, Phillips, Helen, Raal, Frederick, Hovingh, Kees   +4 more
core   +1 more source

Therapeutic novelties in Homozygous Familial Hypercholesterolemia: use of Lomitapide in the pediatric patient

reservedIntroduzione: l’ipercolesterolemia familiare omozigote (HoFH) è una malattia rara, caratterizzata da livelli di colesterolo LDL superiori a 400 mg/dL.
BORTOLUSSI, MICHELE
core